Background: Gene expression profiling (GEP) and donor-derived, cell-free DNA (dd-cfDNA) measurement are alternative methods to endomyocardial biopsy (EMB) to monitor for rejection following heart transplantation. We aim to describe our use of GEP and dd-cfDNA in heart transplant recipients > 1-year post-transplantation.
Methods: This is a single-center, retrospective study in post-transplant recipients. For patients who were > 1-year post-transplantation and deemed to be at elevated clinical risk for rejection, we collected both GEP and dd-cfDNA every 3 months. Baseline characteristics including GEP, dd-cfDNA levels, rejection episodes, and number of biopsies were obtained.
Results: Since July 2019, there were 18 patients being followed with GEP and dd-cfDNA who were > 1-year post-transplantation. Nine EMBs had been performed in seven patients due to as follows; three due to elevated GEP ({greater than or equal to} 34), one due to elevated dd-cfDNA ({greater than or equal to} .20%), two due to elevations of both GEP and dd-cfDNA, two due to clinical rejection and one to follow up a post rejection episode. One of the two biopsies due to elevations of both GEP and dd-cfDNA showed acute cellular rejection grade 2R. None of the biopsies due to either an elevation in the GEP or dd-cfDNA revealed any significant rejection.
Conclusion: In this study, the use of both GEP and dd-cfDNA led to an increased number of EMB in patients > 1-year post-transplantation. Further studies are needed to validate these findings and evaluate long-term consequences of these diagnostic tests in this population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ctr.14548 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Value of Peripheral Blood Gene Expression Profile and Donor-Derived Cellfree DNA for Identifying Persistent Rejection.
Kidney360
October 2024
Division of Nephrology and Comprehensive Transplant Center, Department of Medicine, Northwestern University, Chicago, Illinois.
Key Points: Peripheral blood biomarkers may have value in monitoring kidney transplant recipients after treatment of acute rejection. The donor-derived cellfree DNA may be more sensitive to identifying antibody-mediated rejection and gene expression profile may be more sensitive to identifying acute cellular rejection.
Background: Persistent rejection is an increasingly recognized barrier to long-term kidney allograft survival.
Heart Transplant Rejection: From the Endomyocardial Biopsy to Gene Expression Profiling.
Biomedicines
August 2024
Department of Cell Biology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, 540139 Targu Mures, Romania.
Heart transplant prolongs life for patients with end-stage heart failure but rejection remains a complication that reduces long-term survival. The aim is to provide a comprehensive overview of the current status in HT rejection. EMB is an invasive diagnostic tool, consisting in the sampling of a fragment of myocardial tissue from the right ventricular septum using fluoroscopic guidance.
View Article and Find Full Text PDFClinical Value of Peripheral Blood Gene Expression Profile and dd-cfDNA for Identifying Persistent Rejection.
Kidney360
August 2024
Department of Medicine, Division of Nephrology and Comprehensive Transplant Center, Northwestern University, Chicago, IL.
Background: Persistent rejection is an increasingly recognized barrier to long-term kidney allograft survival. A noninvasive method to help identify patients with persistent rejection in need of biopsy would be valuable.
Methods: This was a post-hoc analysis of a multicenter observational study.
Surveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry.
J Heart Lung Transplant
September 2024
Divison of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, California. Electronic address:
Background: Molecular testing with gene-expression profiling (GEP) and donor-derived cell-free DNA (dd-cfDNA) is increasingly used in the surveillance for acute cellular rejection (ACR) after heart transplant. However, the performance of dual testing over each test individually has not been established. Further, the impact of dual noninvasive surveillance on clinical decision-making has not been widely investigated.
View Article and Find Full Text PDFA gentler approach to monitor for heart transplant rejection.
Front Cardiovasc Med
February 2024
Department of Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, VA, United States.
Article Synopsis
- Current heart transplant rejection diagnosis mainly relies on endomyocardial biopsy, even with advancements in biomarkers and imaging technology.
- New molecular evaluations and imaging techniques are being developed that could reduce the need for invasive biopsies.
- As these non-invasive approaches improve, they might enable more accurate and personalized treatment plans for rejection in heart transplant patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!